Is the snake that just bit you deadly? Venom ‘pregnancy test’ could tell
Cecilie Knudsen placed the urine on one end of the strip, then sat anxiously for 15 minutes to see whether one or two lines appeared. She wasn’t testing for pregnancy. Instead, Knudsen, a biotechnologist and co-founder of VenomAid Diagnostics, was waiting to see whether the test she and her colleagues developed would accurately detect the presence of a particular snake venom in a sample of mouse urine. It did . The finding, published last month in Scientific Reports , represents “a really remarkable step in venom diagnosis,” says Kalana Maduwage, a physician and biochemist at the University ...
Source: ScienceNOW - February 29, 2024 Category: Science Source Type: news

QUICK Rheumatism Capsule, Tiger Wang Biaod contains hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use QUICK Rheumatism Capsule, Tiger Wang Biaod, a product promoted and sold for rheumatism on various websites and possibly in some retail stores. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 29, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

SNAKE BONES Anti-Rheumatic Capsules contains hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use SNAKE BONES Anti-Rheumatic Capsules, a product promoted and sold for rheumatism on various websites and possibly in some retail stores. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 29, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Helps to Deliver Meaningful Advances for Rare Disease Patients
We remain committed to supporting rare disease research, engaging patients and caregivers to understand their unique perspectives, and enhancing our review processes to advance medical products for rare disease patients. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 29, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 29, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Natural History Studies and Registries in the Development of Rare Disease Treatments - 05/13/2024
Natural History Studies and Registries in the Development of Rare Disease Treatments (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 29, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Sociodemographic Characteristics of Adverse Event Reporting
Researchers in CDER ’s Office of Surveillance and Epidemiology and others examined the sociodemographic characteristics of individuals who submit FAERS reports (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 29, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Will 2024 Be Easier on the Eyes? Will 2024 Be Easier on the Eyes?
Longer-acting drugs, novel implants, and oral and topical agents that aim to solve the burden of frequent injections and office visits for retinal disease are on the horizon.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 29, 2024 Category: Drugs & Pharmacology Tags: Ophthalmology Source Type: news

Drug Development Considerations for Empiric Antibacterial Therapy in Febrile Neutropenic Patients - 04/23/2024
The purpose of the public workshop is to discuss clinical trial design and other considerations related to the development of antibacterial drug products for treatment of febrile neutropenia (FN). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Remarks by Commissioner Robert Califf to the AIRIS Workshop - 02/26/2024
Speech by Dr. Robert M. Califf, MD Commissioner of Food and Drugs Airis Workshop Feb. 26, 2004 Seoul, South Korea (by video) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Seladelpar Could'Raise the Bar' in PBC Treatment Seladelpar Could'Raise the Bar' in PBC Treatment
The investigational agent significantly improved liver biomarkers of disease activity and symptoms of pruritus in adults with PBC enrolled in a phase 3 trial.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 28, 2024 Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news

FDA Roundup: February 27, 2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 27, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 27, 2024 Category: Drugs & Pharmacology Source Type: news

FDA Approves Exblifep (cefepime/enmetazobactam) for the Treatment of Complicated Urinary Tract Infections
SAINT-LOUIS, France& WEILL AM RHEIN, Germany February 27, 2024 -- Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 27, 2024 Category: Drugs & Pharmacology Source Type: news

Doxorubicin Ups Breast Cancer Risk in Hodgkin Lymphoma Doxorubicin Ups Breast Cancer Risk in Hodgkin Lymphoma
The findings may have implications for breast cancer surveillance among survivors of Hodgkin lymphoma.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 27, 2024 Category: Drugs & Pharmacology Tags: Hematology-Oncology Source Type: news